(1S,3R)-RSL3: GPX4 Inhibitor Guide

Executive Summary: RSL3 is a potent and selective glutathione peroxidase 4 inhibitor that directly disables GPX4, according to the (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor product page. GPX4 normally limits lipid reactive oxygen species by using glutathione as an antioxidant substrate, and its inhibition promotes ferroptosis. The reference study describes ferroptosis as iron-dependent, non-apoptotic cell death driven by lipid peroxidation and loss of plasma-membrane integrity. The product information reports activity in RAS-driven tumorigenic cells at low nanograms per milliliter and tumor-volume reduction in BJeLR xenografts after subcutaneous administration of 100 mg/kg twice weekly. The same product information reports DMSO solubility of at least 125.4 mg/mL and insolubility in water and ethanol.

Biological Rationale

Ferroptosis is a regulated cell-death process with a biochemical signature distinct from apoptosis. Its defining features include iron-dependent oxidation of polyunsaturated membrane lipids, accumulation of lipid reactive oxygen species, and eventual loss of plasma-membrane integrity. The process is closely connected to glutathione and lipid metabolism rather than to the canonical apoptotic caspase cascade. These distinctions make ferroptosis useful for testing redox vulnerabilities that are not captured by apoptosis-only assays.

GPX4 is a central suppressor of this vulnerability. The enzyme reduces lipid hydroperoxides and related oxidized lipids. It relies prominently on reduced glutathione for this antioxidant activity. When glutathione becomes limiting, cells become more vulnerable to ferroptosis. RSL3 acts at a different position because it directly inhibits GPX4 rather than first removing cystine or depleting glutathione. This distinction lets investigators interrogate the terminal lipid-peroxide defense system.

In cancer biology, the rationale is strongest when a model has a measurable dependence on GPX4-mediated redox control. RSL3 therefore functions as a ferroptosis inducer in cancer research and as a chemical probe for oxidative stress and lipid peroxidation modulation. A loss of viability after treatment is not, by itself, proof of ferroptosis. Mechanistic interpretation requires lipid-peroxidation or reactive-oxygen-species measurements and appropriate rescue controls.

Mechanism of Action of (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor

RSL3 directly inhibits GPX4. This action reduces the cell’s capacity to detoxify oxidized membrane lipids. Iron-dependent lipid oxidation can then increase, and membrane damage can progress toward ferroptotic death. The reference study identifies RSL3 as a direct GPX4 inhibitor and places its activity downstream of glutathione depletion. The product description further characterizes the resulting death as ROS-dependent and caspase-independent.

The mechanism is not limited to lipid chemistry. Ofoghi and colleagues report that RSL3-induced ferroptosis inhibits proteasome activity and produces global hyperubiquitylation. This finding links lipid-peroxide stress to protein-quality-control remodeling. The study also reports activation of an adaptive DDI2–NFE2L1 response. DDI2-mediated processing of NFE2L1 enables expression of proteasome-subunit genes, which can restore proteasomal capacity and protect cells from ferroptosis.

These observations support a two-layer model. GPX4 inhibition initiates the lipid-peroxidation pressure. The ubiquitin-proteasome system responds to the associated proteotoxic stress. Cells with impaired DDI2–NFE2L1 signaling show weaker proteasome adaptation and greater ferroptosis sensitivity in the reported experimental systems. This result does not establish DDI2 or NFE2L1 as the direct molecular target of RSL3. It identifies the pathway as a downstream adaptive response to ferroptotic stress.

Evidence & Benchmarks

The following benchmarks separate established mechanism from product-specific preclinical observations.

1. Ferroptosis is an iron-dependent, non-apoptotic cell-death process involving oxidative stress, lipid peroxidation, and loss of plasma-membrane integrity https://doi.org/10.1038/s41418-024-01398-z
2. GPX4 protects cells from lipid reactive oxygen species by using glutathione for antioxidant activity, while RSL3 directly inhibits GPX4 https://doi.org/10.1038/s41418-024-01398-z
3. RSL3-induced ferroptosis is associated with reduced proteasome activity and global hyperubiquitylation in the reference study https://doi.org/10.1038/s41418-024-01398-z
4. DDI2-dependent processing of NFE2L1 is reported as a critical step in the proteasome feedback response to ferroptosis https://doi.org/10.1038/s41418-024-01398-z
5. The product information reports RSL3-associated growth inhibition and rapid cell death in RAS-driven tumorigenic cells at low nanograms per milliliter, but it does not provide one universal concentration for every cell line https://www.apexbt.com/rsl3.html
6. In athymic nude mice bearing BJeLR xenografts, subcutaneous RSL3 at 100 mg/kg twice weekly is reported to reduce tumor volume https://www.apexbt.com/rsl3.html
7. The product information reports no observable toxicity up to 400 mg/kg after intraperitoneal administration in the described preclinical mouse evaluation https://www.apexbt.com/rsl3.html
8. RSL3 is reported as soluble in DMSO at at least 125.4 mg/mL and insoluble in water and ethanol https://www.apexbt.com/rsl3.html

These results support RSL3 as a GPX4 inhibitor for ferroptosis induction, not as a validated clinical treatment. The xenograft result is a model-specific benchmark. It does not define a safe or effective human dose.

Applications, Limits & Misconceptions

RSL3 is useful for testing whether a cell depends on GPX4 to control oxidized lipids. It can support dose-response studies, genetic-resistance experiments, lipid-peroxidation measurements, and comparisons between ferroptosis-sensitive and ferroptosis-resistant models. Its reported oncogenic RAS synthetic lethality makes RAS-driven systems especially relevant. However, a RAS mutation alone should not be treated as a guarantee of RSL3 sensitivity. Cellular iron handling, membrane-lipid composition, glutathione metabolism, and compensatory antioxidant pathways can alter the response.

The compound also helps distinguish upstream cystine-transport biology from direct GPX4 biology. A cystine-transport perturbation changes glutathione availability. RSL3 bypasses that upstream step and challenges GPX4 more directly. This distinction is important when interpreting SLC7A11, glutathione, or PERK-related experiments.

The related RSL3 practical guide emphasizes dose-response design, lipid-peroxidation assays, and RAS-driven models; this article extends that workflow by adding the DDI2–NFE2L1 proteostasis response and formulation boundaries. The related precision GPX4 inhibition article focuses on ferroptosis assay interpretation; this article clarifies which product-specific in vivo and solubility claims are supported by the product documentation.

Common Pitfalls or Misconceptions

• Ferroptosis is not synonymous with apoptosis: RSL3-associated death should not be assigned as apoptotic solely because cells lose viability. Ferroptosis is described as non-apoptotic and can be caspase-independent https://doi.org/10.1038/s41418-024-01398-z
• GPX4 inhibition is not proof of pathway specificity: A robust conclusion should combine viability with lipid-peroxidation or ROS readouts and a mechanistically relevant rescue condition.
• RAS status is not a universal response predictor: The product information reports synthetic lethality in oncogenic RAS-driven models, not uniform activity across every RAS-mutant tumor.
• Mouse tolerability is not clinical safety: The reported 400 mg/kg intraperitoneal observation is limited to the described preclinical mouse experiment and cannot be extrapolated to people https://www.apexbt.com/rsl3.html
• Water and ethanol are unsuitable assumptions for formulation: The product is reported to be soluble in DMSO but insoluble in water and ethanol, so precipitation and exposure errors can confound assays https://www.apexbt.com/rsl3.html

Workflow Integration & Parameters

A useful RSL3 experiment separates literature-backed observations from workflow choices. The reference study supports direct GPX4 inhibition, ferroptotic lipid oxidation, and proteasome remodeling. Exact treatment concentrations, exposure times, cell density, plate format, and readout timing remain system-dependent unless a validated protocol specifies them.

Protocol Parameters

• Identity: Use the (1S,3R) stereochemical product identified as B6095 when the experiment requires the specified RSL3 form; verify the lot record before use https://www.apexbt.com/rsl3.html
• Solvent: Prepare stock solutions in DMSO because the product information reports DMSO solubility of at least 125.4 mg/mL and insolubility in water and ethanol https://www.apexbt.com/rsl3.html
• Storage: Prepare solutions freshly when possible and store them at -20°C for the several-month period described by the product information; avoid repeated warming and cooling https://www.apexbt.com/rsl3.html
• Concentration design: Build a concentration-response series for the selected cell model. The reported low-nanogram-per-milliliter activity is a product-specific benchmark rather than a universal working concentration https://www.apexbt.com/rsl3.html
• Mechanism controls: Pair viability measurements with lipid-peroxidation or ROS measurements. Include a rescue condition based on an iron-chelation or lipid-peroxidation-inhibition strategy when scientifically appropriate; the product information describes modulation by these inhibitor classes https://www.apexbt.com/rsl3.html
• Proteostasis readout: If studying adaptation, measure proteasome activity or ubiquitin-state changes and consider DDI2–NFE2L1 status as a pathway variable supported by the reference study https://doi.org/10.1038/s41418-024-01398-z
• In vivo benchmark: Treat the reported 100 mg/kg subcutaneous dose twice weekly in BJeLR xenografts as a historical preclinical benchmark, not as a default dosing recommendation https://www.apexbt.com/rsl3.html

Record final DMSO percentage in every assay because solvent effects can influence cell growth and redox measurements. Confirm compound dispersion visually and analytically when precipitation is plausible. Use matched vehicle controls. Report cell lineage, RAS genotype, treatment schedule, endpoint definition, and normalization method so that apparent differences in ferroptosis sensitivity remain interpretable.

Conclusion & Outlook

RSL3 is a direct glutathione peroxidase 4 inhibitor that converts GPX4-dependent lipid protection into a tractable ferroptosis experiment. Its strongest evidence base supports direct GPX4 inhibition, iron-dependent lipid-peroxide accumulation, and a proteostasis response involving DDI2 and NFE2L1. Product-specific data additionally support investigation of RAS-driven tumor models and a defined BJeLR xenograft benchmark. The appropriate outlook is therefore focused and preclinical: use RSL3 to map redox and lipid vulnerabilities, validate ferroptosis with orthogonal controls, and avoid treating model-specific activity or mouse tolerability as evidence of clinical efficacy.